Technical Analysis for CMRX - Chimerix, Inc.

Grade Last Price % Change Price Change
C 1.10 -4.35% -0.05
CMRX closed down 4.35 percent on Monday, March 18, 2024, on 57 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -4.35%
Inside Day Range Contraction -4.35%
New Downtrend Bearish -3.51%
Down 3 Days in a Row Weakness -3.51%
Down 4 Days in a Row Weakness -3.51%
Fell Below 20 DMA Bearish -5.98%

   Recent Intraday Alerts

Alert Time
Down 3% about 13 hours ago
Lower Bollinger Band Support about 14 hours ago
60 Minute Opening Range Breakdown about 14 hours ago
Fell Below Previous Day's Low about 14 hours ago
Down 2 % about 14 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Chimerix, Inc. Description

Chimerix, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of oral antiviral therapeutics for various medical needs. Its lead product includes CMX001, an orally administered drug that has completed Phase II clinical trials for the prevention of cytomegalovirus infection in hematopoietic stem cell transplant recipients; and is in Phase II clinical trials for treating double-stranded DNA viruses comprising herpesviruses, adenoviruses, BK viruses, papillomaviruses, and orthopoxviruses, as well as for the treatment of smallpox. The company also develops CMX157, an oral nucleotide compound that is in Phase I clinical trials to treat HIV infections. It has a collaboration and license agreement with Merck, Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Viruses Virus Hematopoietic Stem Cell Antiviral Drug Herpes Papillomavirus Prodrugs Ebola Monkeypox Poxviruses Antivirals Cytomegalovirus Infection Orthopoxvirus

Is CMRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.57
52 Week Low 0.88
Average Volume 393,176
200-Day Moving Average 1.07
50-Day Moving Average 1.05
20-Day Moving Average 1.19
10-Day Moving Average 1.20
Average True Range 0.07
RSI (14) 44.44
ADX 32.38
+DI 19.20
-DI 22.04
Chandelier Exit (Long, 3 ATRs) 1.10
Chandelier Exit (Short, 3 ATRs) 1.22
Upper Bollinger Bands 1.28
Lower Bollinger Band 1.11
Percent B (%b) -0.06
BandWidth 13.96
MACD Line 0.03
MACD Signal Line 0.05
MACD Histogram -0.0201
Fundamentals Value
Market Cap 97.78 Million
Num Shares 88.9 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -1.15
Price-to-Sales 72.90
Price-to-Book 0.40
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.21
Resistance 3 (R3) 1.22 1.19 1.19
Resistance 2 (R2) 1.19 1.17 1.19 1.18
Resistance 1 (R1) 1.15 1.15 1.14 1.14 1.18
Pivot Point 1.12 1.12 1.12 1.12 1.12
Support 1 (S1) 1.08 1.10 1.07 1.07 1.02
Support 2 (S2) 1.05 1.08 1.05 1.02
Support 3 (S3) 1.01 1.05 1.01
Support 4 (S4) 1.00